Koebenhavn N, Denmark

Jakob Ewald

USPTO Granted Patents = 2 

Average Co-Inventor Count = 9.7

ph-index = 1


Company Filing History:


Years Active: 2024-2025

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Jakob Ewald

Introduction

Jakob Ewald is a notable inventor based in Koebenhavn N, Denmark. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative patents. With a total of two patents to his name, Ewald's work focuses on developing novel compounds that have the potential to impact medical treatments.

Latest Patents

Ewald's latest patents include groundbreaking inventions such as glucose-sensitive albumin-binding derivatives. This invention relates to glucose-sensitive albumin-binding diboron conjugates, providing novel diboron compounds that serve as intermediate compounds for the synthesis of diboron conjugates. Another significant patent is related to new C-type natriuretic peptide (CNP) compounds. This application discusses pharmaceutical compositions comprising these compounds and their use as medicaments.

Career Highlights

Jakob Ewald is associated with Novo Nordisk A/S, a leading global healthcare company. His work at Novo Nordisk has allowed him to focus on innovative research and development in the pharmaceutical sector. Ewald's contributions are vital in advancing medical science and improving patient care.

Collaborations

Ewald has collaborated with esteemed colleagues such as Thomas Kruse and Mikael Kofod-Hansen. These collaborations have fostered a productive environment for innovation and have led to the development of impactful pharmaceutical solutions.

Conclusion

Jakob Ewald's inventive spirit and dedication to research have led to significant advancements in pharmaceutical compounds. His work continues to inspire innovation in the medical field, showcasing the importance of creativity and collaboration in scientific research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…